SCHEMBL669442

SCHEMBL669442

CC(=O)Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.70
SMN1; SMN2 Q16637 3/20 0.70
IDO1 P14902 1/20 0.67
ALDH1A1 P00352 2/20 0.62
TRPV1 Q8NER1 1/20 0.61
KIF11 P52732 2/20 0.59
TGM2 P21980 1/20 0.59
NPC1 O15118 1/20 0.59
RAB9A P51151 1/20 0.59
HTT P42858 2/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
MAPK1 P28482 1/20 0.58
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
TDP1 Q9NUW8 1/20 0.57
LMNA P02545 1/20 0.57
CA12 O43570 1/20 0.57
BRD4 O60885 1/20 0.57
NR1I2 O75469 1/20 0.57
CA1 P00915 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nitrogen SCHEMBL28799837 0.96 SMN1; SMN2 (0.66) EPHX2SMN1; SMN2IDO1ALDH1A1TRPV1
SCHEMBL14384397 0.89 SMN1; SMN2 (0.58) EPHX2SMN1; SMN2IDO1ALDH1A1TRPV1
SCHEMBL23059791 0.89 SMN1; SMN2 (0.58) EPHX2SMN1; SMN2IDO1ALDH1A1TRPV1
SCHEMBL18409061 0.89 NPC1 (0.65) EPHX2SMN1; SMN2IDO1ALDH1A1TRPV1
SCHEMBL16349508 0.86 SMN1; SMN2 (0.68) EPHX2SMN1; SMN2IDO1ALDH1A1KIF11
SCHEMBL19227674 0.85 SMN1; SMN2 (0.59) EPHX2SMN1; SMN2IDO1ALDH1A1TRPV1
SCHEMBL14546864 0.84 SMN1; SMN2 (0.71) EPHX2SMN1; SMN2IDO1ALDH1A1TRPV1
SCHEMBL5544653 0.84 SMN1; SMN2 (0.71) EPHX2SMN1; SMN2IDO1ALDH1A1KIF11
SCHEMBL3415035 0.84 EPHX2 (0.66) EPHX2SMN1; SMN2ALDH1A1TRPV1KIF11
SCHEMBL9784355 0.84 SMN1; SMN2 (0.71) EPHX2SMN1; SMN2IDO1ALDH1A1KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109563043-A SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 葛兰素史密斯克莱知识产权发展有限公司 2019-04-02 CN claimed
CN-103930407-B Aminopyrimidine derivatives useful as modulators of kinase activity 默克专利有限公司 2019-02-26 CN claimed
CN-106946796-A Aminopyridine derivative as modulators of kinase activity 默克专利有限公司 2017-07-14 CN claimed
CN-103906730-A Parp inhibitors HOFFMANN LA ROCHE 2014-07-02 CN claimed
US-4766243-A Electrophilic fluorination of aromatic compounds OCCIDENTAL CHEMICAL CORPORATION (US) 1988-08-23 US claimed
US-20260098041-A1 FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS INCYTE CORPORATION (US) 2026-04-09 US disclosed
US-20250333419-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF WRN INCYTE CORPORATION (US) 2025-10-30 US disclosed
US-20250215006-A1 TRICYCLIC COMPOUNDS AS INHIBITORS OF WRN INCYTE CORPORATION (US) 2025-07-03 US disclosed
CN-115650970-B Thiazolinone compound and preparation method and application thereof 江西科技师范大学 2024-07-16 CN disclosed
CN-118255686-A Fluorine-containing trans-phenyl cyclopropylamine derivative, and preparation method and application thereof 郑州大学 2024-06-28 CN disclosed
CN-113462278-B Varnish composition, method for producing polyimide resin, and additive 东京应化工业株式会社 2024-06-07 CN disclosed
EP-4326721-A1 SPIROCYCLIC IMIDAZOLIDINONES AND IMIDAZOLIDINEDIONES FOR TREATMENT OF LIGHT CHAIN AMYLOIDOSIS Protego Biopharma, Inc. (US) 2024-02-28 EP disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed
US-6235730-B1 ANTICHOLESTEROL AGENT, ANTILIPEMIC AGENT JAPAN TOBACCO, INC. (JP) 2001-05-22 US disclosed
CN-1252068-A 3-piperidyl-4-oxoquinazoline derivatives and pharmaceutical compositions containing the same JAPAN TOBACCO INC (JP) 2000-05-03 CN disclosed
EP-0970954-A1 3-PIPERIDYL-4-OXOQUINAZOLINE DERIVATIVES AND MEDICINCAL COMPOSITIONS CONTAINING THE SAME JAPAN TOBACCO INC. (JP) 2000-01-12 EP disclosed
EP-0246061-B1 A BENZOYLUREA DERIVATIVE AND ITS PRODUCTION AND USE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1992-03-18 EP disclosed
US-4766243-A Electrophilic fluorination of aromatic compounds OCCIDENTAL CHEMICAL CORPORATION (US) 1988-08-23 US disclosed
EP-0246061-A2 A benzoylurea derivative and its production and use SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1987-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 EPHX2 3662/4885SMN1; SMN2 3985/4885IDO1 3181/4885
US-20260098041-A1 FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS WRN, POLR1A, REV1 EPHX2 2786/4885SMN1; SMN2 1169/4885IDO1 1654/4885
US-20250333419-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF WRN WRN, BLM, RECQL EPHX2 2907/4885SMN1; SMN2 1568/4885IDO1 448/4885
US-20250215006-A1 TRICYCLIC COMPOUNDS AS INHIBITORS OF WRN WRN, BLM, RECQL EPHX2 3049/4885SMN1; SMN2 1990/4885IDO1 471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.